Iberdomide is an experimental oral drug being developed by Bristol Myers Squibb (BMS) under its Celgene subsidiary for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow. The drug is a cereblon E3 ligase modulator (CELMoD), a class of agents that work by targeting specific proteins for degradation, similar to but distinct from immunomodulatory drugs like lenalidomide and pomalidomide. Iberdomide is designed to be effective in patients who have become resistant to other treatments, including those who have failed prior lines of therapy with lenalidomide, pomalidomide, and proteasome inhibitors. The drug is being evaluated in multiple clinical trials, including the pivotal Phase 3 CC-220-MM-001 trial for relapsed or refractory multiple myeloma. A New Drug Application (NDA) for Iberdomide was submitted to the U.S. Food and Drug Administration (FDA) in late 2024, with a target action date in 2026. The prediction market asks whether the FDA will grant full approval or accelerated approval by the end of 2026, or whether the drug will face a denial, withdrawal, conditional approval, or no decision. This market is of interest to investors, analysts, and patients because the outcome will affect BMS's revenue projections, the treatment landscape for multiple myeloma, and the prospects for the CELMoD class of drugs. Multiple myeloma is the second most common blood cancer, with an estimated 35,780 new cases and 12,540 deaths in the United States in 2024, according to the American Cancer Society. The disease has a five-year survival rate of about 60%, but patients with relapsed or refractory disease have a poor prognosis, creating a high unmet need for new therapies. Iberdomide has shown promising efficacy in clinical trials, with a response rate of about 30-40% in heavily pretreated patients, and a manageable safety profile. The FDA's decision will be based on the results of the Phase 3 trial and the overall benefit-risk assessment. If approved, Iberdomide would compete with other multiple myeloma drugs such as carfilzomib, daratumumab, and selinexor, as well as other CELMoDs in development like mezigdomide (BMS-986369).

Historical Context

The development of Iberdomide is rooted in the success of immunomodulatory drugs (IMiDs) for multiple myeloma, starting with thalidomide in the late 1990s. Thalidomide was initially approved for multiple myeloma in 2006 after showing efficacy in clinical trials, despite its notorious history of causing birth defects. Celgene then developed lenalidomide (Revlimid), which was approved in 2006 for transfusion-dependent anemia in myelodysplastic syndromes and later for multiple myeloma. Lenalidomide became a blockbuster, with peak annual sales of over $12 billion before generic competition began in 2022. Pomalidomide (Pomalyst) followed in 2013 for patients who had failed lenalidomide and bortezomib. These drugs work by binding to the protein cereblon and modulating the ubiquitin-proteasome system, leading to degradation of transcription factors essential for myeloma cell survival. Iberdomide is a next-generation CELMoD that is more potent than previous IMiDs and designed to overcome resistance. The drug was discovered by Celgene scientists and entered Phase 1 clinical trials in 2016. The Phase 2 portion of the trial showed an overall response rate of 31% in patients who had received a median of 5 prior lines of therapy, including 86% who were refractory to lenalidomide. The FDA granted Iberdomide Orphan Drug Designation for multiple myeloma in 2017 and Fast Track Designation in 2020. The Phase 3 CC-220-MM-001 trial, which began in 2021, compares Iberdomide plus dexamethasone to standard-of-care regimens in patients with relapsed or refractory multiple myeloma. The trial completed enrollment in 2023, with results expected in 2024. The NDA submission in late 2024 triggered a standard 10-month review cycle, setting the target action date in 2026. The FDA's decision will be influenced by precedent: the agency has approved several multiple myeloma drugs based on Phase 2 data with accelerated approval, including selinexor in 2019 and idecabtagene vicleucel in 2021. However, the FDA has also become more stringent in requiring confirmatory trials for accelerated approvals, as seen with the withdrawal of some indications for drugs like bevacizumab in breast cancer.